Europe’s preparedness will only be as strong as its vaccine and biotech base
Europe cannot afford to rediscover preparedness only when the next crisis arrives. COVID-19 exposed deep vulnerabilities in health security, manufacturing
Read moreEurope cannot afford to rediscover preparedness only when the next crisis arrives. COVID-19 exposed deep vulnerabilities in health security, manufacturing
Read moreToday, European patients wait on average more than 578 days to access new medicines after approval from the European Medicines
Read moreEurope has enormous strengths in science, manufacturing and its industrial base, but struggles to translate this into investment, clinical trials
Read moreThe future of European biotech may be taking shape in a former factory in Delft. A familiar building to me.
Read moreSix years after the COVID-19 pandemic fundamentally changed our perception of health security, one lesson remains undeniable: preparedness is not
Read moreFor the past decades, Europe has been treating biotechnology primarily as a health policy issue. That was a mistake. Biotech
Read moreHealth sovereignty today is not defined by physical control alone: stockpiles, warehouses or emergency reserves. Those still matter, but the
Read moreA sector already delivering for Europe Europe remains one of the world’s leading vaccine development and manufac turing ecosystems and
Read more